With nearly a quarter billion in Q1, J&J targets $100B revenue in 2026
BioSpace
With robust sales performance from oncology darling Darzalex and immunology superstar Tremfya, Johnson & Johnson is "off to a fast start in 2026," CEO Joaquin Duato told investors on Tuesday.
pharminent
April 14, 2026 (Last updated: April 14, 2026)
BioSpace
With robust sales performance from oncology darling Darzalex and immunology superstar Tremfya, Johnson & Johnson is “off to a fast start in 2026,” CEO Joaquin Duato told investors on Tuesday.
